PTC Therapeutics Inc. Common Stock (PTCT)

About PTCT

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; T…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

991

Website

www.ptcbio.com/

Fundamentals

1-day range

$69.61$71.23

Market cap

$5.68B

P/E (trailing)

—

P/E (forward)

28.04

EPS (trailing)

$-0.59

Dividend yield

—

Beta

0.48

Avg. volume

1.68M

Forecasts

14 analyst ratings

PTC Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• PTCT

  PTC Therapeutics Inc. Common Stock

  $70.01

  ▼ 2.51%
  Market cap $5.68BP/E —
  $48.86$90.87
• KNSA

  Kiniksa Pharmaceuticals International plc Class A Ordinary Shares

  $78.1

  ▼ 2.13%
  Market cap $5.73BP/E 75.29
  $33.25$82.94
• DNTH

  Dianthus Therapeutics Inc. Common Stock

  $105.72

  ▼ 5.22%
  Market cap $5.80BP/E —
  $22.81$117.88
• LGND

  Ligand Pharmaceuticals Incorporated Common Stock

  $280

  ▼ 1.59%
  Market cap $5.85BP/E 38.07
  $158.4$326.63
• GRFS

  Grifols S.A. American Depositary Shares

  $7.68

  ▼ 1.79%
  Market cap $5.40BP/E 13.31
  $8.43$12.87
• BLTE

  Belite Bio Inc American Depositary Shares

  $151.65

  ▼ 3.42%
  Market cap $6.09BP/E —
  $62.18$200
• ERAS

  Erasca Inc. Common Stock

  $18.03

  ▼ 7.49%
  Market cap $6.11BP/E —
  $1.33$24.28

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• PTC Therapeutics To Present New Sephience Data At The 2026 Society For The Study Of Inborn Errors Of Metabolism Annual Symposium, August 25-28
  benzinga · 8/24/2026
• Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122
  Benzinga · 8/14/2026
• PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'
  Benzinga · 8/13/2026
• Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109
  Benzinga · 8/13/2026
• PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript
  SeekingAlpha · 8/13/2026
• PTC Therapeutics To Acquire BLA-Stage ST-920 Fabry Disease Program; Terms Include $111M Upfront And Up To $100M In Contingent Milestone Payments Based On Certain Regulatory Approvals
  Benzinga · 8/12/2026
• PTC Therapeutics (PTCT) Stock Fair Value Edges Higher After Analyst Target Increases
  Yahoo · 8/5/2026
• PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
  Yahoo · 8/4/2026
• Top 3 Health Care Stocks You'll Regret Missing This Quarter
  Benzinga · 8/4/2026

• Matthew B. Klein · August 4, 2026 · Sale

  10.3K @ $68.57
• Hege Elisabeth Sollie-Zetlmayer · July 28, 2026 · Grant

  1.7K
• Hege Elisabeth Sollie-Zetlmayer · July 28, 2026 · Grant

  3.5K
• Hege Elisabeth Sollie-Zetlmayer · July 28, 2026 · Grant

  2.0K
• Hege Elisabeth Sollie-Zetlmayer · July 28, 2026 · Grant

  4.0K
• Pierre Gravier · July 14, 2026 · Sale

  3.5K @ $80.35
• Mary L. Smith · July 9, 2026 · Option Exercise

  5.8K @ $42.95
• Mary L. Smith · July 9, 2026 · Option Exercise

  10.0K @ $42.95
• Mary L. Smith · July 9, 2026 · Sale

  5.8K @ $90
• Mary L. Smith · July 9, 2026 · Sale

  10.0K @ $90
• Neil Gregory Almstead · July 9, 2026 · Option Exercise

  2.5K @ $46.54
• Neil Gregory Almstead · July 9, 2026 · Sale

  2.5K @ $90.25
• Neil Gregory Almstead · July 7, 2026 · Option Exercise

  24.6K @ $39.42
• Neil Gregory Almstead · July 7, 2026 · Sale

  9.3K @ $89.44
• Neil Gregory Almstead · July 7, 2026 · Sale

  11.4K @ $89.03

Institutional Ownership

March 31, 2026

Total shares held

90.57M

Total value held

$6.02B

Institutional holders

343